Rationale: Cardiac membrane excitability is tightly regulated by an integrated network of membrane-associated ion channels, transporters, receptors, and signaling molecules. Membrane protein dynamics in health and disease are maintained by a complex ensemble of intracellular targeting, scaffolding, recycling, and degradation pathways. Surprisingly, despite decades of research linking dysfunction in membrane protein trafficking with human cardiovascular disease, essentially nothing is known regarding the molecular identity or function of these intracellular targeting pathways in excitable cardiomyocytes. Objective: We sought to discover novel pathways for membrane protein targeting in primary cardiomyocytes. Methods and Results: We report the initial characterization of a large family of membrane trafficking proteins in human heart. We used a tissue-wide screen for novel ankyrin-associated trafficking proteins and identified 4 members of a unique Eps15 homology (EH) domain-containing protein family (EHD1, EHD2, EHD3, EHD4) that serve critical roles in endosome-based membrane protein targeting in other cell types. We show that EHD1-4 directly associate with ankyrin, provide the first information on the expression and localization of these molecules in primary cardiomyocytes, and demonstrate that EHD1-4 are coexpressed with ankyrin-B in the myocyte perinuclear region. Notably, the expression of multiple EHD proteins is increased in animal models lacking ankyrin-B, and EHD3-deficient cardiomyocytes display aberrant ankyrin-B localization and selective loss of Na/Ca exchanger expression and function. Finally, we report significant modulation of EHD expression following myocardial infarction, suggesting that these proteins may play a key role in regulating membrane excitability in normal and diseased heart. Conclusions: Our findings identify and characterize a new class of cardiac trafficking proteins, define the first group of proteins associated with the ankyrin-based targeting network, and identify potential new targets to modulate membrane excitability in disease. Notably, these data provide the first link between EHD proteins and a human disease model. (Circ Res. 2010;107:84-95.)
M embrane trafficking, endocytosis, and endocytic recycling of integral membrane proteins are critical cellular functions for normal membrane excitability and cardiomyocyte physiology. Mechanistically, these cellular pathways are controlled by highly organized protein networks that tightly regulate anterograde and retrograde trafficking of membrane proteins, their stability at the cell surface, and their degradation following internalization. Whereas the last few years have witnessed the identification and preliminary characterization of these protein networks in cultured cells, essentially nothing is known regarding these pathways in primary excitable cells, including cardiomyocytes. In fact, the field of molecular cardiology lacks fundamental understanding even of the identity of these critical trafficking proteins in primary cardiac tissue.
Ankyrins are a family of proteins required for membrane targeting and stability of membrane ion channels, transporters, cell adhesion molecules, and signaling proteins. 1 The importance of ankyrins for normal physiology is illustrated by human diseases linked with ankyrin dysfunction and mice lacking ankyrin gene products. In heart, ankyrins have key roles in the membrane trafficking and regulation of sodium and calcium channels, Na/Ca exchanger (NCX), Na/K ATPase, and inositol 1,4,5-trisphosphate (IP3) receptor. 2 Ankyrin-B dysfunction is associated with a human arrhythmia syndrome affecting multiple excitable cell types resulting in sinus node disease, atrial fibrillation, conduction defects, catecholaminergic polymorphic ventricular arrhythmia, and sudden death. [3] [4] [5] [6] Although ankyrins are recognized as critical components for anterograde targeting of ion channels and transporters, little is known regarding the underlying molecular machinery and associated proteins required for ankyrin-based trafficking.
Here, we report the initial characterization of a family of membrane trafficking proteins in human heart. We used a tissue-wide screen for novel ankyrin-associated trafficking proteins and identified 4 members of a family of EH (Eps15 homology) domain-containing (EHD) gene products (EHD1-4) that provide critical roles for endosome-based membrane protein targeting and recycling in other cell types. Specifically, EHD proteins regulate endosomal anterograde and retrograde trafficking, as well as membrane protein recycling and lipid homeostasis. [7] [8] [9] We report that EHD1-4 directly associate with ankyrin and provide the first information on the expression and localization of these molecules in cardiomyocytes. EHD1-4 are expressed with ankyrin-B in the myocyte perinuclear region and EHD expression is increased in ankyrin-B-deficient hearts. Myocytes deficient in EHD3 display striking loss of NCX membrane trafficking and function, thus establishing the first functional role for cardiac EHD proteins. Finally, we report modulation of EHD expression in a large animal model of arrhythmias, suggesting that these proteins may play a key role in regulating membrane excitability in normal and diseased heart. Together, our findings identify a new class of cardiac membrane trafficking proteins, define the first group of proteins associated with the cardiac ankyrin-based targeting network, and identify potential new targets to modulate membrane excitability in human disease.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Statistics
Values are expressed as meansϮSEM. Probability values were assessed with a Student's t test or ANOVA, as appropriate. The Bonferroni test (electrophysiological measurements) or least squares difference was used for post hoc testing. The null hypothesis was rejected for PϽ0.05. To analyze immunoblot densitometric measurements from multiple experiments on EHD expression across species and heart chambers, immunoblot bands were normalized to actin and then to a control (human or left ventricle), resulting in a mean value of one with no standard error for the control group.
Protein Modeling
Modeling of EHD2 was performed using Cn3D4.1 software based on the EHD2 structure of Daumke et al. 8 
In Vitro Binding
Protein products were in vitro translated using the TNT Coupled Reticulocyte Lysate System and labeled with [ 35 S]methionine. Products were incubated with glutathione S-transferase (GST) fusion proteins of ankyrin-B and ankyrin-G domains (MBD, SBD, CTD) in 500 L of binding buffer (50 mmol/L Tris [pH 7.4], 1 mmol/L EDTA, 1 mmol/L EGTA, 150 mmol/L NaCl, 0.1% Triton X-100 and protease inhibitor) overnight at 4°C. GST-protein complexes were washed 5 times (50 mmol/L Tris [pH 7.4], 1 mmol/L EDTA, 1 mmol/L EGTA, 500 mmol/L NaCl, 0.1% Triton X-100), and analyzed by SDS-PAGE. To visualize equal loading of GST proteins, gels were stained with Coomassie Blue. [ 35 S]-labeled products that bound GST-ankyrin fusion proteins were detected by phosphorimaging. All binding experiments were replicated Ͼ3 times.
Results

Ankyrin-B Associates With Key Membrane Trafficking Protein
Loss of ankyrin-B results in the development of a proarrhythmic substrate caused by the loss of membrane expression of a select group of critical cardiac ion channels and transporters. 4 -6 As a first step in defining the key molecular components of the cardiac ankyrin-B-based membrane trafficking pathway, we performed a screen for novel ankyrin-binding proteins. We screened a human heart yeast 2-hybrid library with the central region of ankyrin-B as bait for candidate interacting proteins with specific roles in protein trafficking, vesicle fusion, or organelle biogenesis. A screen of Ͼ2 million independent clones identified 1 such candidate (Figure 1A) . Sequencing of a Ϸ500-bp clone revealed a nucleotide match with NM_014600.1 that encodes residues 192 to 349 of the human EHD3 protein ( Figure 1A ). Previously unidentified in human cardiac tissue, this protein is a member of the 4-member human EHD protein family (EHD1-4) with recently defined roles in membrane protein trafficking in other cell types. 10, 11 Notably, the ankyrin-binding partial sequence bears strong similarity to the corresponding sequences in EHD1 (86% identical), EHD2 (77% identical), and EHD4 (78% identical) ( Figure 1A ). Like EHD3, these other EHD products have not been previously studied in heart.
EHD3 Directly Interacts With Ankyrin-B
We confirmed the ankyrin-B/EHD3 interaction in vitro using radiolabeled full-length EHD3 and bacterially expressed and affinity-purified ankyrin-B fused to GST. Full-length EHD3 cDNA was cloned from a human heart cDNA library and in vitro translated in the presence of [ 35 S]methionine. Consistent with the 2-hybrid screen, we observed interaction of radiolabeled EHD3 with GST-ankyrin-B ( Figure 1B and 1C membrane-binding domain that primarily associates with ion channels and transporters, a spectrin-binding domain that associates with cytoskeletal and signaling proteins, and a C-terminal domain that modulates ankyrin function in vivo ( Figure 1B ). We observed specific interaction of EHD3 with the ankyrin-B membrane-binding domain ( Figure 1C ). In contrast, GST-ankyrin-B spectrin-binding domain, GSTankyrin-B C-terminal domain, and GST alone lacked EHD3 binding ( Figure 1C ). Moreover, despite Ϸ75% amino acid identity with the ankyrin-B membrane-binding domain, the ankyrin-G (product of ANK3 gene) membrane-binding domain lacked EHD3 binding activity ( Figure 1C ). We also observed no interaction of EHD3 with the ankyrin-G spectrin-binding domain or C-terminal domain ( Figure 1C ). Moreover, EHD3 did not associate with a third ankyrinfamily gene product, ankyrin-R (data not shown). Therefore, EHD3 directly associates with ankyrin-B in vitro. This interaction is specific to ankyrin-B versus other ankyrin-gene products and requires the ankyrin-B membrane-binding domain.
EHD Proteins Associate With Ankyrin-B
Whereas yeast and in vitro binding studies ( Figure 1A through 1C) demonstrated that ankyrin-B can associate with EHD3, human EHD3 protein paralogs display high amino acid identity across all domains ( Figure 1D and 1E). Although EHD3 is most similar to EHD1 (87% identity), EHD2 and EHD4 sequences also closely resemble EHD3 (71% and 75% amino acid identity, respectively). We therefore tested whether ankyrin-B associates with multiple EHD proteins. Consistent with the high homology of EHD proteins, particularly within the EHD central region, we observed association of ankyrin-B with all EHD proteins ( Figure 1F through 1I). Specifically, purified GST-ankyrin-B membrane-binding domain interacts with radiolabeled full-length EHD1, EHD2, EHD3, and EHD4 ( Figure 1F through 1I). In contrast, radiolabeled EHD proteins (EHD1-4) displayed no binding activity for GST alone. Similar to findings with EHD3 ( Figure 1C ), we observed no interaction of ankyrin-G with EHD1, -2, or -4.
EHD3 Interaction With Ankyrin Requires Coiled-Coil Domain
EHD proteins display a conserved primary structure consisting of a short N-terminal region (NT), a dynamin-like domain (DLD) that includes the nucleotide-binding "P-loop" known to bind ATP (together, N-terminal domain and DLD often referred to as "G-domain"), a "coiled-coil" region, and a C-terminal EH domain that binds to NPF motifs in target proteins (Figure 2A through 2C). The EH domain consists of 2 EF hands of which the second is capable of binding to Ca 2ϩ ; this is thought to be important for the folding of the EH domain. In addition to associating with Ca 2ϩ , lipid, and membrane trafficking proteins, EHD proteins form homoand heterooligomers via their coiled-coil region. Nucleotide binding at the P-loop also regulates membrane-binding and oligomerization (Figure 2A through 2C ). Therefore, we investigated the structural requirements on EHD3 for ankyrin-binding activity. We generated a library of mutants corresponding to each EHD3 domain/region ( Figure 2D ). Additionally, we created mutants corresponding to all combinations of EHD3 domains ( Figure 2D ). Each EHD3 mutant was radiolabeled and incubated with purified GST-ankyrin-B or GST. We observed consistent interaction with ankyrin-B for all EHD3 mutants that contained the coiled-coil region ( Figure 2D and 2E). In contrast, the EHD3 N-terminal region, DLD, and EH domain lacked ankyrin-binding activity. We observed no binding of any EHD3 mutant with GST ( Figure  2E ). Thus, we have defined the structural requirements on both ankyrin-B and EHD3 for interaction. Specifically, the ankyrin-B membrane-binding domain is critical for EHD3binding activity, whereas the coiled-coil region mediates the EHD3 interaction with ankyrin-B. It is noteworthy that the association of the EHD coiled-coil region with ankyrin-B is 8 (EHD2) to illustrate potentially exposed sites on the polypeptide. Yellow denotes AMP-PNP molecule in structure. D, Library of protein mutants generated for mapping the ankyrin-binding region on EHD3. E, Purified GST-ankyrin-B membrane-binding domain (MB) associates with radiolabeled EHD3 mutants containing the coiled-coil domain. We observed background binding for all other mutants. Input (In) and control binding to GST alone (Cn) are also shown. All binding data were successfully replicated in 4 independent experiments. Note that the translated DLD/CC/EHD product displays a second, slightly smaller (migrates Ϸ3 kDa lower) degradation product that also associates with ankyrin-B.
the first assigned non-EHD protein binding partner for this domain.
EHD Family Proteins Are Expressed in Vertebrate Heart
Four genes encode EHD proteins in vertebrates. However, to date, there is no detailed information on the cellular expression, localization, or function of any of these gene products in human heart. We first performed RT-PCR from normal human left ventricle to establish the presence of EHD1-4 message in human heart. All EHD mRNA products were observed in left ventricle, and sequencing revealed matches with full-length EHD1-4 cDNAs previously identified from noncardiac sources ( Figure 3A ). Consistent with mRNA findings, we observed EHD1-4 proteins by immunoblot using isoform-specific antibodies on human left ventricle ( Figure  3B ). Parallel lysates prepared from mouse, rat, and canine left ventricle demonstrated expression of EHD1-4 ( Figure  3B through 3F) . Finally, immunoblots of normal human heart chambers revealed EHD1-4 expression in all cardiac chambers ( Figure 3G through 3K) . Together, these findings demonstrate that the all members of the EHD protein family (EHD1-4) are expressed in heart across a range of vertebrates. Finally, we tested the ability of each EHD-containing protein to interact with ankyrin-B in cardiac tissue lysates. In agreement with in vitro binding assays, ankyrin-B associates with all EHD-containing polypeptides in heart. Specifically, coimmunoprecipitation studies using affinity-purified ankyrin-B immunoglobulin and detergent-soluble lysates from adult mouse heart demonstrate interaction of ankyrin-B with EHD1-4 (Online Figure I) . This interaction was specific to ankyrin-B, because no EHD interaction was observed with control immunoglobulin (Online Figure I) , or with ankyrin-G or ankyrin-R (data not shown). Collectively, our data provide the first evidence for the cellular expression of the EHD protein family across vertebrates.
EHD Proteins Are Localized to Cardiomyocyte Perinuclear Region
To date, the cellular distribution of any EHD-containing protein in any cardiac cell type is unknown. We defined the subcellular distribution of EHD1-4 in heart using primary cardiomyocytes and EHD isoform-specific antibodies. 12 Although not fully differentiated, neonatal myocytes were chosen for these studies, because these cells are thin (Ϸ2 m in x-z dimension compared with Ϸ20 m in adult myocytes), which allows optimal imaging of the organelles involved in the membrane targeting pathway. In neonatal cardiomyocytes, ankyrin-B is localized to cytoskeleton-enriched domains underlying the myocyte membrane ( Figure 4A through 4D, left) . In addition, ankyrin-B is localized to the perinuclear region of cardiomyocytes ( Figure 4A through 4D). EHD1-4 -positive staining was observed in clusters near the perinuclear region ( Figure 4 ). This is similar to the localization of EHD proteins in HeLa cells, where they reside in endosomes and regulate trafficking through this endocytic compartment. 11, 13 Together, these findings establish the subcellular distribution of EHD proteins in isolated primary ventricular cardiomyocytes.
Loss of Ankyrin-B Affects EHD1-4 Expression and Localization in Heart
To examine the functional relationship between ankyrin-B and EHD proteins, we evaluated the expression of EHD polypep- tides in hearts of adult wild-type and ankyrin-B ϩ/Ϫ mice (ankyrin-B Ϫ/Ϫ mice die immediately after birth). Interestingly, EHD1-4 levels were not reduced in ankyrin-B ϩ/Ϫ hearts. Instead, we observed significant increases in all EHD protein levels ( Figure 5A through 5E; nϭ7/genotype; PϽ0.05). These findings strongly support a relationship between ankyrin-B and EHD proteins in heart. We further examined the relationship of ankyrin-B and EHD1-4 at the level of the single cell by examining the distribution of all EHD proteins in isolated primary cardiomyocytes lacking ankyrin-B. In agreement with immunoblot data, expression of all EHD-containing proteins (EHD1-4) was increased in the complete absence of ankyrin-B ( Figure 5F through 5M). EHD1 expression was increased in the perinuclear region of ankyrin-B Ϫ/Ϫ neonatal cardiomyocytes ( Figure 5F and 5G ). Increased peripheral cytoplasmic staining was observed for both EHD2 and EHD3 in ankyrin-B Ϫ/Ϫ cardiomyocytes ( Figure 5H through 5K ). Finally, EHD4 showed a strong increase preferentially in the perinuclear area of ankyrin-B Ϫ/Ϫ cells ( Figure 5L and 5M ).
EHD3 Overexpression Selectively Increases Myocyte I NCX
Ankyrin-B is critical for targeting select cardiac ion channels and transporters. Myocytes lacking ankyrin-B expression display decreased membrane expression and function of NCX1, whereas the localization and function of the L-type Ca 2ϩ channel, Ca v 1.2, is unaffected. 2, 5, 14, 15 We therefore assessed the ability of EHD overexpression to enhance ankyrin-B-associated protein membrane expression and function. As expected, whole-cell patch clamp recordings revealed a decrease in membrane NCX current (I NCX ) in ankyrin-B Ϫ/Ϫ cardiomyocytes, consistent with the notable perinuclear localization in ankyrin-B Ϫ/Ϫ myocytes ( Figure  6A through 6C) . Specifically, we observed differences in whole-cell I NCX at nearly all voltages in ankyrin-B Ϫ/Ϫ cardiomyocytes compared with wild-type myocytes (nϭ12 cells/ genotype, PϽ0.05). Overexpression of human green fluorescent protein (GFP)-EHD3 increased I NCX in wild-type cardiomyocytes at select voltages compared with untransfected myocytes ( Figure 6D Figure 6J and 6K; nϭ12 cells/genotype/treatment, PϭNS). Together, these data support the requirement of ankyrin-B for anterograde delivery of select myocyte membrane proteins to the cell surface. Moreover, these data demonstrate that EHD3 overexpression enhances this cellular pathway in wild-type cardiomyocytes.
EHD3 Is Required for NCX Membrane Expression and Function
We further probed the role of EHD3 for myocyte function by reducing EHD3 expression using EHD3-specific small inter- fering (si)RNA. Notably, myocytes lacking EHD3 expression (see Online Figure II ) displayed striking reduction in targeting and function of I NCX (Figure 7A, 7C, 7D , 7F, and 7G; nϭ11 cells/treatment for I NCX experiments, PϽ0.05). Moreover, EHD3-deficient cardiomyocytes displayed defects in the localization (Figure 7F and 7G; note decreased expression and prominent large cytosolic puncta) and expression (see Online Figure II , PϭNS) . Together, these data provide the first functional evidence of a role for EHD3 in the membrane trafficking of a critical cardiac transporter. Moreover, the notable selectivity of the targeting defect (NCX versus Ca v 1.2), as well as the direct affect of EHD3 knockdown on ankyrin-B expression, strongly supports a role for EHD3 in the cardiac ankyrin-B membrane protein trafficking pathway.
EHD Proteins Are Differentially Regulated in Cardiovascular Disease
Aberrant ankyrin-B regulation is observed in rare forms of congenital arrhythmia. 4 Moreover, common variants in the ankyrin-B gene (ANK2) modulate cardiac function in the general human population. 16 Finally, ankyrin-B expression is significantly reduced in a large animal model of arrhythmias following myocardial infarction (MI). 17 In contrast, there are no data on the role of EHD1-4 in human arrhythmia or in animal models of human disease. As a first step in identifying a potential role of EHD proteins in disease, we examined the expression of EHD1-4 in a well-validated large-animal (canine) model of arrhythmias following MI. 17, 18 Forty-eight hours after coronary artery occlusion, we observed an increase in EHD3 expression in a specific heart region where arrhythmias originate (infarct border zone) compared to control tissue (remote from infarct; remote EHD3 levels are no different from remote regions of noninfarcted hearts at 48 hours or 5 days after occlusion: 1.19Ϯ0.05 and 1.11Ϯ0.10, respectively; PϭNS compared to control; nϭ3) ( Figure 8A and 8B). By 5 days after occlusion (when action potential and ion channel changes are most prominent 19 ), we observed significant increases in both EHD3 and EHD4 levels in the infarct border zone ( Figure 8A and 8B ). EHD1 and EHD2 levels were not significantly changed at 48 hours or 5 days after occlusion ( Figure 8A and 8B) . Notably, ankyrin-B levels are reduced in this post-MI arrhythmia model (representative immunoblots shown in Figure 8 ). 17
Discussion
Our findings identify the EHD family of endosomeassociated proteins as novel components of the ankyrin-Bbased targeting pathway in heart. Specifically, ankyrin-B directly associates with EHD1-4 via a conserved sequence in the coiled-coil domain. EHD proteins are expressed in human heart and are coexpressed with ankyrin-B in the perinuclear region of cardiomyocytes. Our findings define the first group of ankyrin-B-associated proteins that are not negatively affected by ankyrin-B loss. In fact, loss of ankyrin-B results in increased EHD1-4 expression. Myocytes lacking EHD3 expression phenocopy ankyrin-B Ϫ/Ϫ myocytes, displaying both decreased expression and function of NCX, but maintaining the expression and activity of Ca v 1.2. Finally, we demonstrate dramatic alteration of the EHD proteins following MI, suggesting that these proteins may play an important role in action potential and ion channel changes in heart disease. Our findings provide the initial functional character-ization of a new class of membrane trafficking proteins in heart and provide the first reported link between EHD proteins and a human disease model. We believe these findings open a new avenue to understand the molecular determinants of cardiac membrane excitability.
EHD proteins appear to regulate endosomal anterograde and retrograde trafficking, as well as membrane protein recycling and lipid homeostasis. 7, 8, 20 Structural analysis has revealed a similarity of EHD2 with the dynamin superfamily. This similarity may translate into parallel functional roles of EHD-containing proteins with dynamin, including the ability to tubulate liposomes, dimerize, oligomerize around lipid tubules in ring-like structures, and stimulate nucleotide hydrolysis in response to lipid binding. 8 Among EHD proteins, EHD1 is the best characterized, with roles in membrane recycling of the transferrin receptor, major histocompatibility class 1 receptor, and ␤ 1 integrin. 20 Additionally, EHD1 associates directly with phosphatidylinositol compounds 21, 22 and modulates cholesterol homeostasis. 23 Although molecular mechanisms underlying EHD1 function are still being identified, EHD1-binding partners including MICAL-L1, 13 ARF6, and Rab effector proteins argue that EHD1 plays a central role in endosome/Golgi vesicular trafficking. 7, 8, 11, 24 Similarly, EHD2 regulates glucose-stimulated GLUT4 membrane transport and endocytosis in adipocytes. 25 Potentially relevant for cardiac muscle, EHD2 interactions with myoferlin are important for myoblast fusion. 26 Additionally, EHD1 has been demonstrated to interact with amphiphysin-1, 27 a member of a protein family implicated in biogenesis of transverse tubules in skeletal muscle. 28 Finally, both EHD3 and EHD4 have roles in endosome vesicular targeting and recycling. 29, 30 Specifically, EHD3 directly associates with critical trafficking proteins including Rab11-FIP2. 11 Finally, 2 reports describe testicular phenotypes in mouse models of EHD1 and EHD4 deficiency. Deletion of EHD1 and EHD4 31, 32 result in reduction in testes size; however, deletion of EHD1 leads to male infertility, whereas deletion of EHD4 does not. In summary, although much is unknown about the roles of these recently identified proteins, the clear linkage of EHD proteins with protein trafficking, endocytosis, and endocytosis suggests that these proteins may have critical roles in controlling trafficking of membrane proteins that maintain cardiac excitability.
Loss of ankyrin-B in this study resulted in increased EHD family protein expression. Based on these findings, we hypothesize that that the EHD/ankyrin in vivo interaction occurs either upstream or concurrently with the interaction of ankyrin with membrane-associated proteins. Thus, in response to loss of ankyrin-B-associated proteins at the membrane, the myocyte may attempt to augment anterograde membrane trafficking by upregulating the EHD/ankyrin pathway. EHD protein expression levels may also be regulated by the local signaling environment. 33, 34 Thus, abnormal ion homeostasis created by the loss of ankyrin-B 3,5 may trigger a parallel ankyrin-independent EHD-containing protein pathway to accelerate anterograde membrane protein trafficking. Interestingly, EHD3 and EHD4 expression was increased in the canine model of MI that also shows parallel loss of ankyrin-B (Figure 8 ). 17 Clearly, additional studies in adult cardiomyocytes and in vivo will be necessary to carefully evaluate the functional relationship between EHD proteins and ankyrin-B.
Finally, based on the demonstrated roles of EHD proteins in other tissues, 9, 12 we predict that loss of EHD-containing proteins in heart will affect cardiac membrane protein regulation and excitability. In support of this hypothesis and in agreement with our findings in neonatal cardiomyocytes, we observed striking perinuclear staining for all EHD proteins (EHD1-4) in adult cardiomyocytes (Online Figure III) . Our findings that EHD proteins are upregulated in animal models of cardiovascular disease suggest that this pathway may be a nodal point for the regulation of electric remodeling in the myocyte damaged by aberrant Na ϩ or Ca 2ϩ homeostasis or myocyte membrane damage/ischemia. However, based on previous findings in other tissues and high sequence identity, together with our results that ankyrin-B interacts with all EHD proteins, we predict that cardiac EHD-containing proteins may display functional redundancy in the constitutive absence of a single family member in the context of an animal. For example, whereas EHD4-deficient mice display defects in germ cell development and testis size, changes in the levels of EHD1-3 likely prevents EHD4 Ϫ/Ϫ mice from displaying more overt phenotypes. 31, 32 Interestingly, a proportion of EHD1-deficient mice are neonatal lethal 35 because of unknown causes. Future work will help unravel whether this is attributable to defects in cardiac excitability. Thus, although siRNA experiments may be effective in assessing phenotypes in isolated cells acutely (Figure 7) , elucidating the physiological relevance of EHD proteins in vivo may in fact require knockout of multiple EHD protein isoforms. 
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